United States Patent 11,890,270: Tecovirimat Form I Scope, Validity, and Patent Landscape

U.S. Patent No. 11,890,270 protects treatment of orthopoxvirus infections with crystalline Form I of tecovirimat, also known as ST-246, when the administered material exhibits a specified X-ray powder diffraction profile. The patent is a solid-state and method-of-treatment patent, not a broad composition-of-matter patent covering tecovirimat in every physical form. Its commercial value depends on whether marketed or proposed generic tecovirimat contains Form I, whether the product is used for a claimed indication, and whether the patent is listed for the relevant FDA product.

The strongest claim is claim 1, which combines four limitations: the disease category, treatment with tecovirimat, the Form I polymorph, and a defined set of 32 XRPD peaks. Claim 8 is narrower by disease but potentially broader in other respects because it does not expressly require the purity thresholds or oral administration recited in claims 2 through 7.

What drug does U.S. Patent 11,890,270 protect?

U.S. Patent 11,890,270 concerns tecovirimat, the active ingredient in SIGA Technologies' TPOXX product. Tecovirimat is an antiviral approved by the FDA for treatment of human smallpox caused by variola virus in adults and pediatric patients. The FDA later approved an intravenous formulation for patients unable to take oral therapy or for whom oral administration is not appropriate.[1]

The chemical name in the claims is:

4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-benzamide.

The claims identify the protected material by its solid form rather than solely by chemical structure. This distinction matters because the same active pharmaceutical ingredient can exist as different polymorphs, solvates, hydrates, amorphous material, or mixtures of solid forms.

Attribute	Patent 11,890,270
Active ingredient	Tecovirimat, ST-246
Product association	TPOXX
Patent subject	Form I polymorph and therapeutic use
Primary disease scope	Orthopoxvirus infections
Specific disease in claim 8	Eczema vaccinatum
Dosage route expressly claimed	Oral administration in claim 7
Solid-form identifier	XRPD peak pattern
Purity limitations	At least about 70%, 80%, 90%, 95%, or 99% free of other forms
Patent type	Solid-state pharmaceutical and method-of-treatment patent
Grant number	U.S. 11,890,270

What are the independent claims in Patent 11,890,270?

The patent has two independent method claims.

Claim 1: Orthopoxvirus treatment with Form I

Claim 1 covers administering a therapeutically effective amount of Form I tecovirimat to a subject requiring treatment for an orthopoxvirus infection. The Form I material must show the claimed XRPD peaks at approximately:

7.63, 10.04, 11.47, 14.73, 15.21, 15.47, 16.06, 16.67, 16.98, 18.93, 19.96, 20.52, 20.79, 22.80, 25.16, 26.53, 27.20, 27.60, 29.60, 30.23, 30.49, 30.68, 31.14, 33.65, 34.33, 35.29, 35.56, 36.30, 37.36, 38.42, and 38.66 degrees 2θ.

The phrase “orthopoxvirus infections” is materially broader than smallpox. It can encompass infections associated with variola virus, monkeypox virus, cowpox virus, vaccinia virus, and other orthopoxviruses, subject to the patent's construction and supporting disclosure.

Claim 8: Eczema vaccinatum

Claim 8 covers treating eczema vaccinatum with the same Form I material and XRPD profile. Eczema vaccinatum is a severe complication associated with vaccinia virus exposure or vaccination in individuals with atopic dermatitis or other eczematous skin disease.

Claim 8 does not expressly include the purity thresholds in claims 2 through 6. It also does not expressly require oral administration. A product could therefore fall within claim 8 based on the Form I XRPD limitation even if the asserted product does not satisfy the dependent purity or route limitations.

How do the dependent claims narrow the patent scope?

Claims 2 through 6 define increasing levels of Form I purity:

Claim	Limitation
Claim 2	At least about 70% free of other forms
Claim 3	At least about 80% free of other forms
Claim 4	At least about 90% free of other forms
Claim 5	At least about 95% free of other forms
Claim 6	At least about 99% free of other forms
Claim 7	Oral administration

These claims create a graded infringement structure. A product containing 92% Form I may potentially satisfy claim 4 but not claim 5 or claim 6, depending on the analytical method and how “free of other forms” is construed.

The purity limitations also create evidentiary issues. The patent owner would likely need to establish the proportion of Form I and other solid forms through validated solid-state testing. Relevant evidence could include XRPD, differential scanning calorimetry, thermogravimetric analysis, microscopy, solid-state nuclear magnetic resonance, and batch records.

What is the scope of the XRPD limitation?

The XRPD limitation is the central technical limitation in the patent. It distinguishes Form I from other tecovirimat forms by requiring a characteristic diffraction pattern.

The words “about” and “characteristic peaks” provide flexibility but do not eliminate the need for analytical proof. A court would likely examine:

The permitted angular deviation around each listed peak.
The radiation source and instrument configuration.
Whether relative peak intensity matters.
Whether all 32 peaks must be present.
The effect of sample preparation, crystallinity, particle size, and preferred orientation.
Whether the claim requires a single crystalline form or permits mixtures containing Form I.
The meaning of “free of other forms” in the dependent claims.

A generic applicant could attempt to design around the patent by using a different polymorph, an amorphous form, a solvate, or a formulation in which the active ingredient does not exhibit the claimed Form I pattern. That approach would not eliminate risk if the manufacturing process converts the material into Form I during isolation, storage, formulation, or administration.

What patents protect tecovirimat beyond Patent 11,890,270?

Tecovirimat's patent estate should be separated into four categories.

Composition-of-matter patents

Earlier patents may protect the tecovirimat chemical entity or related substituted benzamide compounds. These patents provide the broadest chemical protection but generally expire earlier than later solid-form patents because their patent terms run from earlier priority or nonprovisional filing dates.

Solid-form and polymorph patents

Patent 11,890,270 belongs to this category. Solid-form patents can extend commercial protection after expiration of the original compound patent if they cover the form used in the approved product.

Method-of-use patents

Method patents may cover treatment of smallpox, monkeypox, eczema vaccinatum, or other orthopoxvirus conditions. Their enforceability depends on the accused product's labeling, marketing, prescribing patterns, and induced-infringement evidence.

Formulation and manufacturing patents

Separate rights may cover:

Oral dosage forms.
Intravenous formulations.
Crystalline-form production.
Solvent systems.
Purification and crystallization processes.
Particle-size control.
Stability-enhancing compositions.
Large-scale manufacturing methods.

Manufacturing patents are especially relevant because a generic applicant may avoid direct product claims but still face process-patent exposure if it uses a protected crystallization or purification route.

When does tecovirimat lose exclusivity?

Tecovirimat does not have one single exclusivity date. The relevant timetable includes FDA regulatory exclusivity, compound patents, method patents, formulation patents, and solid-form patents.

Protection category	Commercial effect
FDA new-drug exclusivity	Blocks certain abbreviated applications for the statutory exclusivity period
Orphan-drug exclusivity, if applicable	Can restrict approval of the same drug for the same rare disease or condition
Compound patent	Broadest chemical protection, usually earliest expiration
Method-of-use patent	Can restrict labeled or promoted uses
Formulation patent	Can restrict a specific dosage form or delivery route
Polymorph patent	Can restrict products containing the claimed solid form
Manufacturing patent	Can restrict production methods even if the final product claim is avoided

TPOXX received FDA approval in 2018 for oral treatment of smallpox. The FDA approved the intravenous formulation in 2022.[1] The existence of a later-issued Form I patent does not, by itself, establish a particular expiration date. Patent term depends on the earliest effective nonprovisional filing date, any patent-term adjustment, terminal disclaimer, patent-term extension, and the relevant family relationship.[2]

A reliable expiration analysis therefore requires the full USPTO continuity and term-adjustment record. The grant number alone does not establish the terminal expiration date.

What is the Orange Book status of Patent 11,890,270?

Orange Book listing must be analyzed against the specific FDA-approved product and NDA. FDA rules permit listing of patents that claim the drug substance, drug product, or an approved method of use.[3]

For Patent 11,890,270, the key listing questions are:

Whether the patent is listed against the TPOXX NDA.
Whether the listing identifies the oral product, the intravenous product, or both.
Whether the listed claims correspond to an approved formulation or method of use.
Whether the FDA accepted the patent as a drug-product, drug-substance, or method-of-use patent.
Whether the patent is subject to a use code limiting its scope.

A polymorph patent may qualify for listing if it claims the drug substance or an approved drug product containing that form. A method claim directed to eczema vaccinatum may face a narrower listing analysis if that indication is not included in the approved labeling.

The Orange Book should be checked by patent number and NDA rather than by searching only the active ingredient. Listing status can change through additions, delistings, corrections, and patent-term updates.[3]

Are there Paragraph IV challenges to tecovirimat patents?

A generic applicant seeking approval before expiration of listed patents could file a Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed.[4]

For Patent 11,890,270, likely Paragraph IV theories would include:

Noninfringement

The applicant could argue that its tecovirimat is not Form I, does not show the claimed XRPD profile, contains insufficient Form I, or is not marketed for a claimed method.

Anticipation

An invalidity challenge could rely on earlier disclosures of the same polymorph, XRPD pattern, preparation method, or use. A prior-art reference would need to disclose the claimed combination, not merely tecovirimat as a chemical compound.

Obviousness

The challenger could argue that selecting or optimizing Form I was predictable based on known polymorphism, crystallization experiments, thermodynamic stability, or routine solid-form screening. The patent owner would likely respond with evidence of unexpected stability, manufacturability, bioavailability, purity, or storage performance.

Indefiniteness

Potential issues include the meaning of “about,” “characteristic peaks,” and “free of other forms.” The specification and prosecution history would control how much analytical variation the claims permit.

Written description and enablement

The challenger could question whether the patent adequately supports the full orthopoxvirus scope and the purity ranges from 70% to 99%. The patent owner would rely on examples, characterization data, and the relationship between Form I and the claimed therapeutic uses.

No Paragraph IV filing, ANDA litigation, settlement, or launch date should be inferred solely from the patent claims. Those events require confirmation in FDA records, district-court dockets, or the patent owner's public disclosures.

How strong is the patent estate for TPOXX?

The estate is strongest where the commercial product uses the claimed Form I material and the patent covers the same route and indication appearing in the product's labeling.

Risk factor	Assessment
Chemical-entity coverage	Depends on earlier compound patents, not claim 1 of Patent 11,890,270
Form-I coverage	Potentially strong if TPOXX's active ingredient matches the XRPD profile
Oral-product exposure	Directly addressed by claim 7
Eczema vaccinatum exposure	Directly addressed by claim 8
Broad orthopoxvirus exposure	Claim 1 is broader than a smallpox-only use
Analytical enforceability	Depends on reproducible XRPD and purity testing
Design-around potential	Meaningful through a different solid form or formulation
Manufacturing exposure	Depends on separate process patents
Biosimilar risk	Not applicable because tecovirimat is a small-molecule drug
Generic risk	Depends on patent listings, term, ANDA timing, and Paragraph IV activity

The patent is more commercially significant as a product-specific barrier than as a standalone monopoly over tecovirimat. A generic could avoid infringement only if it can consistently manufacture and supply a non-Form-I product or otherwise avoid the claimed use and solid-state limitations.

How does Patent 11,890,270 compare with biologic patent estates?

Tecovirimat is a small molecule, so biosimilar rules do not apply. Generic applicants would use the ANDA pathway under section 505(j), not the abbreviated biologics license application pathway under section 351(k).[5]

The principal difference is substitution and formulation risk. A biosimilar applicant generally addresses reference-product similarity, immunogenicity, and biologic manufacturing complexity. A tecovirimat generic applicant must address chemical equivalence, solid-state identity, dissolution, stability, bioequivalence, and patent certifications.

The Form I limitation can complicate generic development because two products may contain the same active ingredient but differ in crystallinity, polymorph, particle size, or manufacturing history.

What generic launch scenarios exist for tecovirimat?

Three launch scenarios are commercially relevant.

Launch after all blocking patents expire

This is the lowest litigation-risk scenario but may occur after the principal commercial opportunity has narrowed.

Paragraph IV launch after litigation

A generic may launch after prevailing in litigation, obtaining a covenant not to sue, securing a settlement date, or accepting the risk of damages and injunctive relief.

Form-specific design-around launch

A generic may seek approval for a non-Form-I product. This path still requires regulatory and technical proof that the proposed material remains outside the patent claims throughout manufacturing and shelf life.

The practical risk is highest if the approved TPOXX product uses Form I at high purity and the patent is listed against the relevant NDA. In that situation, the patent can create a direct ANDA certification issue even if the generic's active ingredient is chemically identical.

Key Takeaways

Patent 11,890,270 protects treatment methods using Form I tecovirimat identified by a 32-peak XRPD profile.
Claim 1 covers treatment of orthopoxvirus infections and is broader than the eczema vaccinatum claim.
Claims 2 through 6 add Form I purity thresholds from at least about 70% to at least about 99%.
Claim 7 specifically covers oral administration.
Claim 8 focuses on eczema vaccinatum and does not expressly require the dependent purity or oral-route limitations.
The patent does not broadly claim every tecovirimat product or every tecovirimat polymorph.
The main technical enforcement issue will be proving the accused product's solid form and purity.
Tecovirimat has no biosimilar pathway because it is a small molecule.
Generic risk depends on Orange Book listing, patent-family term, Paragraph IV activity, and the ability to develop a stable non-Form-I product.
The patent's exact expiration date cannot be determined from the claims alone; USPTO continuity, terminal-disclaimer, patent-term-adjustment, and patent-term-extension records control.

FAQs

Does Patent 11,890,270 cover TPOXX?

It may cover TPOXX if the active ingredient in the relevant TPOXX product is Form I tecovirimat exhibiting the claimed XRPD pattern and the product is used for a claimed indication. Product-specific coverage depends on the product's solid-state characterization and Orange Book status.

Can a generic tecovirimat product use a different polymorph?

A different polymorph may avoid the literal Form I limitation, but the applicant must establish that the product does not convert to Form I during manufacturing, storage, formulation, or testing. Separate compound, formulation, method, or manufacturing patents may still apply.

Does the patent cover monkeypox treatment?

Claim 1 recites orthopoxvirus infections, a category that can include monkeypox virus infection. Infringement would still depend on the accused product containing the claimed Form I material and on the applicable method-of-use analysis.

Is eczema vaccinatum an FDA-approved TPOXX indication?

The patent claim and the FDA-approved label are separate matters. Patent claim 8 covers treatment of eczema vaccinatum, but claim coverage does not establish that FDA labeling includes that indication.

Is a patent covering a polymorph a composition-of-matter patent?

A polymorph patent protects a particular solid form of a chemical compound. It is narrower than a basic composition-of-matter patent, which generally covers the chemical entity without limiting it to one crystalline form.

References

U.S. Food and Drug Administration. (2018). FDA approves the first drug with an indication for treatment of smallpox.
U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension guidance.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions and patent certifications.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application pathway for generic drugs.
U.S. Patent No. 11,890,270. (2024). Polymorph of ST-246. United States Patent and Trademark Office.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Siga Technologies	TPOXX	tecovirimat	CAPSULE;ORAL	208627-001	Jul 13, 2018		RX	Yes	Yes	11,890,270	⤷ Start Trial				TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2549871	⤷ Start Trial	122022000033	Germany	⤷ Start Trial
European Patent Office	2549871	⤷ Start Trial	22C1023	France	⤷ Start Trial
African Regional IP Organization (ARIPO)	3221	⤷ Start Trial
Argentina	083435	⤷ Start Trial
Australia	2011232551	⤷ Start Trial
Brazil	112012023743	⤷ Start Trial
Canada	2793533	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,890,270

Which drugs does patent 11,890,270 protect, and when does it expire?

Summary for Patent: 11,890,270